Mobile

A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000244-24

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to model the dose response of UK-390,957 at week 8 and to define the least effective dose in the ≤2 minutes population, based on Intervaginal Ejaculatory Latency Time as the primary endpoint.

Critère d'inclusion

  • premature ejaculation

Liens